Foley attorneys filed two amicus briefs with the Federal Circuit in the AMP et al. v. USPTO et al.
(ACLU v. Myriad), a much discussed case relating to gene patents. Foley attorneys submitted one brief on behalf of Rosetta Genomics and George Mason University
. Different Foley attorneys also filed a different brief on behalf of Alnylam Pharmaceuticals
. Both briefs conclude that isolated DNA composition claims are patent eligible under current law, and should continue to meet the threshold of 35 U.S.C. § 101 when applying scientific facts to the law.